Publication: The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish oncology group study
dc.contributor.author | Caner, Burcu | |
dc.contributor.buuauthor | CANER, BURCU | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Tıbbi Onkoloji Bilim Dalı | |
dc.contributor.researcherid | AAE-8549-2022 | |
dc.date.accessioned | 2024-06-04T07:06:44Z | |
dc.date.available | 2024-06-04T07:06:44Z | |
dc.date.issued | 2021-07-31 | |
dc.description | Çalışmada 26 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. | |
dc.description.abstract | Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. | |
dc.identifier.doi | 10.1007/s00432-021-03748-7 | |
dc.identifier.endpage | 1508 | |
dc.identifier.issn | 0171-5216 | |
dc.identifier.issn | 1432-1335 | |
dc.identifier.issue | 6 | |
dc.identifier.pubmed | 34331582 | |
dc.identifier.startpage | 1501 | |
dc.identifier.uri | https://doi.org/10.1007/s00432-021-03748-7 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00432-021-03748-7 | |
dc.identifier.uri | https://hdl.handle.net/11452/41705 | |
dc.identifier.volume | 148 | |
dc.identifier.wos | 000679766900001 | |
dc.indexed.pubmed | PubMed | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Springer | |
dc.relation.journal | Journal of Cancer Research and Clinical Oncology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Chemotherapy | |
dc.subject | Therapy | |
dc.subject | Program | |
dc.subject | Time | |
dc.subject | Osimertinib | |
dc.subject | Non-small cell lung cancer | |
dc.subject | Egfr | |
dc.subject | T790m | |
dc.subject | Second line | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Oncology | |
dc.title | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish oncology group study | |
dc.type | Article | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Tıbbi Onkoloji Bilim Dalı | |
relation.isAuthorOfPublication | 9807c94e-65ab-4632-b31b-dc9b1db15d7d | |
relation.isAuthorOfPublication.latestForDiscovery | 9807c94e-65ab-4632-b31b-dc9b1db15d7d |
Files
Original bundle
1 - 1 of 1